Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables
/in Dendritic Cells, Glioblastoma, International PublicationsAutologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study
/in Dendritic Cells, Gastric Cancer, International PublicationsCurrent State of Dendritic Cell-Based Immunotherapy: Opportunities for Antigen Loading of Different DC Subsets?
/in Dendritic Cells, International PublicationsDoes the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
/in Dendritic Cells, International PublicationsHealth-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy
/in Dendritic Cells, International Publications, Malignant MelanomaThe Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage
/in Dendritic Cells, Glioblastoma, International PublicationsCombination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients‘ preference-based study (PPPS)
/in Dendritic Cells, International Publications, NSCLCEmpowering dendritic cell cancer vaccination: the role of combinatorial strategies
/in Dendritic Cells, International PublicationsLong-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines
/in Dendritic Cells, International Publications, Pancreatic Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer